Type: Live attenuated vaccine (LAV) candidate to induce immunity and protect against SARS-CoV-2, developed on Meissa’s codon deoptimized RSV vaccine platform by modifying the company’s respiratory syncytial virus (RSV) LAV candidate MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein.
2021 Status: Meissa told GEN on March 17 that development of MV-014-210 had been discontinued. The company has since pursued development of a vaccine with a slightly different construct, MV-014-212.
2020 Status: Meissa said June 30 that it initiated preclinical studies and manufacturing and completed a pre-IND meeting with the FDA for the development of MV-014-210. The company said MV-014-210 offers significant potential advantages for global deployment that include needle-free intranasal administration, a single adjuvant-free dose to induce systemic and mucosal immunity, and a straightforward, economical, and scalable manufacturing process capable of supplying global demands.
Clinical trials are expected to begin at the end of 2020, Meissa said.
COVID-19: 300 Candidates and Counting
To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: